|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:BME_(Madrid_Stock_Exchange)
|
|
gptkbp:acquisition
|
gptkb:Alkahest
gptkb:Progenika_Biopharma
gptkb:Progenity,_Inc.
gptkb:Biotest_AG
gptkb:Talecris_Biotherapeutics
|
|
gptkbp:ceo
|
gptkb:Victor_Grifols_Deu
|
|
gptkbp:clinical_trial
|
ongoing
in infectious diseases
for neurological disorders
in neurology
for pain management
for rare diseases
for Alzheimer's disease
for COVID-19 convalescent plasma
for COVID-19 treatment
for Guillain-Barré syndrome
for autoimmune disorders
for cancer treatment
for cardiovascular diseases
for dermatological conditions
for endocrine disorders
for gastrointestinal diseases
for genetic disorders
for hemophilia
for infectious diseases
for inflammatory diseases
for kidney diseases
for liver diseases
for metabolic disorders
for multiple sclerosis
for primary immunodeficiency
for respiratory diseases
for sepsis
for transplant medicine
for wound healing
in autoimmune diseases
in hematology
for chronic inflammatory demyelinating polyneuropathy
|
|
gptkbp:employees
|
over 24,000
|
|
gptkbp:founded
|
gptkb:1940
|
|
gptkbp:founder
|
gptkb:Victor_Grifols_Roura
|
|
gptkbp:global_presence
|
gptkb:Europe
gptkb:Middle_East
gptkb:Asia
gptkb:Latin_America
gptkb:North_America
|
|
gptkbp:headquarters
|
gptkb:Barcelona,_Spain
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Grifols
|
|
gptkbp:industry
|
gptkb:Company
|
|
gptkbp:market
|
plasma products
|
|
gptkbp:operates_in
|
over 30 countries
|
|
gptkbp:partnership
|
gptkb:International_Plasma_Protein_Association
gptkb:FDA
gptkb:World_Health_Organization
gptkb:National_Hemophilia_Foundation
gptkb:European_Medicines_Agency
gptkb:NHS_Blood_and_Transplant
gptkb:charity
|
|
gptkbp:philanthropy
|
gptkb:Grifols_Foundation
|
|
gptkbp:product_line
|
albumin
IVIG
coagulation factors
hyperimmune globulins
|
|
gptkbp:production_location
|
in the USA
|
|
gptkbp:products
|
diagnostic products
hospital products
plasma-derived medicines
|
|
gptkbp:research_and_development
|
focus on immunology
|
|
gptkbp:revenue
|
€5.3 billion (2020)
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
|
|
gptkbp:subsidiary
|
gptkb:Grifols_Diagnostic_Solutions
|
|
gptkbp:sustainability_initiatives
|
environmental responsibility
|